Science and Discovery

Lung Cancer

3 articles

Microscopic view of lung cancer cells being targeted by Pfizer's lorlatinib, illustrating a breakthrough in targeted cancer therapy and improved patient survival rates.
Cosmos & Space

Pfizer lung cancer drug: 60% progression-free after five years

After five years, 60% of patients with a specific type of lung cancer treated with Pfizer's lorlatinib were still alive without their disease progressing, a dramatic finding compared to just 8% on the

Marcus Cole·June 23, 2026
A glowing blood sample in a vial, representing a new 14-protein blood test for predicting lung cancer risk.
Cosmos & Space

Researchers find 14-protein blood test predicting lung cancer risk

In a groundbreaking re-analysis, an existing anti-inflammatory drug nearly halved lung cancer risk in individuals identified by a specific 14-protein blood signature.

Marcus Cole·June 9, 2026
A dimly lit laboratory with a microscope, symbolizing the disappointment of a failed Parkinson's drug trial.
Cosmos & Space

Merck Halts Parkinson's Drug Program After Phase 3 Setback

Merck's Parkinson's drug, preladenant, was discontinued in 2026 after Phase 3 trials showed it was no more effective than a placebo.

Aram Sarkisian·May 22, 2026